Wheeler Bio Announces Oversubscribed $35M Series, Plans for Expansion and Continued Growth
OKLAHOMA CITY–(BUSINESS WIRE)–Wheeler Bio, an innovative contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing of antibody-based therapies, announced the closing of an oversubscribed Series A-1 financing round. The $35 million…